12:00 AM
Sep 22, 2016
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Myeloid leukemia cell differentiation protein (MCL1); eukaryotic translation initiation factor 4B (EIF4B)


INDICATION: Breast cancer

Patient sample and cell studies suggest inhibiting EIF4B or MCL1 could help treat basal breast cancer. In tumor samples from breast cancer patients, MCL1 levels were higher in the aggressive basal breast cancer subtype...

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >